Mindfulness: Difference between revisions
>Josikins Grammatics |
>Josikins Grammatics |
(No difference)
| |
Revision as of 21:33, 20 December 2017
Mindfulness can be described as a psychological concept which is well established within the scientific literature and commonly discussed in association with meditation. It is often broken down into two separate components which both comprise the experience of mindfulness itself.
The first of these components involves the self-regulation of attention so that its focus is completely directed towards immediate experience, thereby quietening one's internal narrative and allowing for increased recognition of external and mental events within the present moment.
The second of these components involves adopting a particular orientation toward one’s experiences in the present moment that is characterized by a lack of judgement, curiosity, openness, and acceptance.
Within meditation, this state of mind is deliberately practiced and maintained via the conscious and manual redirection of one's awareness towards a singular point of focus for extended periods of time. However, within the context of psychoactive substance usage, this state is often spontaneously induced without any conscious effort or the need of any prior knowledge regarding meditative techniques.
Although mindfulness usually occurs spontaneously with no immediate trigger, it is considerably more common when the person is also undergoing both anxiety suppression and focus enhancement. It primarily occurs under the influence of heavy dosages of hallucinogenic compounds such as psychedelics, dissociatives, cannabinoids. However, it can also occur on entactogens, certain nootropics such as l-theanine, and during simultaneous doses of benzodiazepines and stimulants
Psychoactive substances
Compounds within our psychoactive substance index which may cause this effect include:
- 2C-C
- 4-AcO-DMT
- 4-AcO-DiPT
- 4-HO-DPT
- 5-Hydroxytryptophan
- 5-MeO-DMT
- 5F-AKB48
- 5F-PB-22
- 6-APB
- 6-APDB
- APICA
- Alpha-GPC
- Aniracetam
- Ayahuasca
- Bromo-DragonFLY
- Bufotenin
- Butylone
- Cannabidiol
- Cannabis
- Citicoline
- Coluracetam
- DMT
- Escaline
- Ethylone
- Ibogaine
- LSA
- LSZ
- MDA
- MDAI
- MDEA
- MDMA
- MET
- Meclofenoxate
- Memantine
- N-Acetylcysteine
- Oxiracetam
- Phenethylamine (compound)
- Phenylpiracetam
- Piracetam
- Pramiracetam
- Progesterone
- Psilocin
- Psilocybin mushrooms
- SAM-e
- STS-135
- THJ-018
- THJ-2201
- Theanine
Experience reports
Anecdotal reports which describe this effect within our experience index include:
- Experience: 36mg 4-AcO-DiPT - Truly, one for the psychedelic animals among us
- Experience: 5-EAPB (60mg) + 2-FMA (20mg) + 4-AcO-DMT (10mg) - Emotional catharsis
- Experience:100-350mg - Phenylpiracetam in daily life
- Experience:120µg LSD - First Bad Acid Trip, Psychosis
- Experience:2.5g Syrian rue + 6g Mimosa Hostilis - My first experience with unity
- Experience:225mg Pregabalin +Cannabis -Bliss and Serenity; a hedonistic evening
- Experience:3 Grams of Mushrooms - Reset on my Life, Experiencing Satori and the Cosmic Perspective
- Experience:60mg 4-AcO-DMT Nonstop Quasi-Orgasmic Objectless Euphoria
- Experience:BK-2C-B - Various experiences
- Experience:Mushrooms (~0.5 g) - Autonomous Voice
- Experience:Mushrooms and Snuff Films -- Trip Report (3.5 grams)
- Experience:Psilocybin Mushroom (0.16 g, Oral) - Dosage Independent Intensity